| Online-Ressource |
Verfasst von: | Zatloukal, Petr [VerfasserIn]  |
| Cardenal, F. [VerfasserIn]  |
| Szczesna, A. [VerfasserIn]  |
| Gorbunova, V. [VerfasserIn]  |
| Moiseyenko, V. [VerfasserIn]  |
| Zhang, X. [VerfasserIn]  |
| Cisar, L. [VerfasserIn]  |
| Soria, J. -C. [VerfasserIn]  |
| Domine, M. [VerfasserIn]  |
| Thomas, Michael [VerfasserIn]  |
Titel: | A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease |
Verf.angabe: | P. Zatloukal, F. Cardenal, A. Szczesna, V. Gorbunova, V. Moiseyenko, X. Zhang, L. Cisar, J. -C. Soria, M. Domine & M. Thomas |
E-Jahr: | 2010 |
Jahr: | September 2010 |
Umfang: | 7 S. |
Illustrationen: | 1 Diagramm |
Fussnoten: | Gesehen am 17.04.2024 |
Titel Quelle: | Enthalten in: Annals of oncology |
Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1990 |
Jahr Quelle: | 2010 |
Band/Heft Quelle: | 21(2010), 9 vom: Sept., Seite 1810-1816 |
ISSN Quelle: | 1569-8041 |
Abstract: | Background - This study compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in small-cell lung cancer patients with extensive disease. - Patients and methods - Patients were randomly assigned to receive cisplatin 80 mg/m2 and either irinotecan 65 mg/m2, days 1 and 8 or etoposide 100 mg/m2, days 1-3, every 3 weeks. - Results - Baseline characteristics were balanced between patients receiving IP (N = 202) or EP (N = 203). Median overall survival was nonsignificantly superior for patients receiving IP versus EP, 10.2 versus 9.7 months [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.65-1.01, P = 0.06] and 1- and 2-year survival rates were 41.9% versus 38.9% and 16.3% versus 8.2%, respectively. Noninferiority of IP versus EP was established, upper bound of the 95% CI of HR 1.01 (prespecified margin IP/EP <1.25). Overall response (39.1% versus 46.6%) and time to tumor progression (5.4 versus 6.2 months) were not superior for IP. Grade 3/4 vomiting (10.9% versus 4.4%) and diarrhea (15.4% versus 0.5%) were more common in the IP versus EP arm; grade 3/4 neutropenia was more frequent in the EP (59.6%) versus IP arm (38.1%). - Conclusions - Our data demonstrate the noninferiority of IP versus EP for survival in primarily Western patients with SCLC-ED. A meta-analysis is required to finally assess the role of irinotecan in this setting. |
DOI: | doi:10.1093/annonc/mdq036 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1093/annonc/mdq036 |
| Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419400598 |
| DOI: https://doi.org/10.1093/annonc/mdq036 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | cisplatin |
| etoposide |
| irinotecan |
| small-cell lung cancer with extensive disease |
K10plus-PPN: | 1886034699 |
Verknüpfungen: | → Zeitschrift |
¬A¬ multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease / Zatloukal, Petr [VerfasserIn]; September 2010 (Online-Ressource)